CARSK stands for the "Canadian-Australasian Randomised Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease."
CARSK is an investigator-initiated, multicentre, non-inferiority, two-parallel-arm randomized trial. It aims to test the hypothesis that after screening for waitlist entry, no further screening for coronary artery disease (CAD) is not inferior to the current standard care, which is screening all asymptomatic waitlisted patients for CAD at regular intervals.
Additionally, it will compare the benefits and costs of not screening versus regular CAD screening from a health system perspective.
Why is this trial important?
Cardiovascular disease is the commonest cause of death while on the kidney transplant waitlist and after transplantation. Current standard care involves screening for coronary artery disease prior to waitlist entry, then every 1-2 years, according to perceived risk, until transplanted. This current screening strategy is not evidence based, has substantial known and potential harms, and is very costly.
Auckland City Hospital in Auckland, NZ has randomised 209 participants.
St. Paul's Hospital in Vancouver, Canada has randomised 183 participants.
Westmead Hospital in Sydney, Australia has randomised 170 participants.
Royal Prince Alfred Hospital in Sydney, Australia has randomized 152 participants.
Vancouver General Hospital in Vancouver, Canada has randomised 112 participants
The University Health Network in Toronto, Canada has randomised 61 participants.
Bellvitge Hospital in Barcelona, Spain has randomised 46 participants.
Royal North Shore Hospital in Sydney, Australia has randomised 46 participants.
St Joseph's Healthcare in Hamilton, Canada has randomised 38 participants.
London Health Sciences Centre in London, Canada has randomised 36 participants.
McGill University Health Centre in Montreal, Canada has randomised 33 participants.
The Ottawa Hospital in Ottawa, Canada has randomised 32 participants.
Box Hill Hospital in Melbourne, Australia has randomised 30 participants.
Wellington Hospital in Wellington, NZ has randomised 26 participants.
University of Montreal, Maisonneuve-Rosemont in Montreal, Canada has randomised 26 participants.
Queen Elizabeth II Health Sciences in Halifax, Canada has randomised 25 participants.
St. George Hospital in Kogorah, Australia has randomised 24 participants.
St. George's University Hospitals in London, England has randomised 24 participants.
The George Washington University in Washington, DC, USA has randomised 23 participants.
Royal University Hospital in Saskatoon, Canada has randomised 23 participants.
Monash Medical Centre in Clayton, Australia has randomised 19 participants.
Dunedin Hospital in Dunedin, NZ has randomised 17 participants.
Austin Hospital in Heidelberg, Australia has randomised 17 participants.
University of Montreal (CHUM) in Montreal, Canada has randomised 17 participants.
St Michael's Hospital in Toronto, Canada has randomised 16 participants.
Kingston General Hospital in Kingston, Canada has randomised 15 participants.
Royal Adelaide Hospital in Adelaide, Australia has randomised 13 participants.
Laval University in Laval, Canada has randomised 12 participants.
Prince of Wales Hospital in Randwick, Australia has randomised 10 participants.
Christchurch Hospital in Christchurch, NZ has randomised 10 participants.
Cairns Hospital in Cairns North, Australia has randomised 10 participants.
University of Alberta Hospital in Edmonton, Canada has randomised 10 participants.
St. Helier Hospital in Sutton, England has randomised 9 participants.
The Charité in Berlin, Germany has randomised 8 participants.
University of Arizona in Tuscon, Arizona, USA has randomized 8 participants.
University Hospitals Sussex in Brighton, England has randomised 6 participants.
Wollongong Hospital in Wollongong, Australia has randomised 4 participants.
King's College Hospital in London, England has begun screening participants
About the logo The logo is two overlapping kidneys in the shape of a heart. The colours are those of the flags of New Zealand, Australia, and Canada, the main participating countries in this trial. Logo design by Jesse Horner.